K. Brameld

发表

The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists.

Christian Laurence, Jérôme Graton, C. Laurence, 2009, Journal of medicinal chemistry.

De novo fragment design: a medicinal chemistry approach to fragment-based lead generation.

A. M. Giannetti, S. Harris, J. D. de Vicente, 2013, Journal of medicinal chemistry.

Quinolones as HCV NS5B polymerase inhibitors.

J. R. Somoza, J. Janc, K. Brameld, 2011, Bioorganic & medicinal chemistry letters.

The Proteome‐Wide Potential for Reversible Covalency at Cysteine

B. Cravatt, Vincent M Crowley, K. Brameld, 2019, Angewandte Chemie.

The proteome-wide potential for reversible covalency at cysteine.

J. M. Bradshaw, B. Cravatt, Vincent M Crowley, 2019, Angewandte Chemie.

Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.

D. Davis, A. Railkar, Amy D. Fung, 2014, Journal of medicinal chemistry.

Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.

Amy D. Fung, S. Harris, S. Le Pogam, 2013, Journal of medicinal chemistry.

Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

J. M. Bradshaw, A. Johnson, P. Porcu, 2014, The Journal of Biological Chemistry.

Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis

B. Kuhn, M. Stahl, K. Brameld, 2008, J. Chem. Inf. Model..

Substrate Distortion to a Boat Conformation at Subsite −1 Is Critical in the Mechanism of Family 18 Chitinases

William A. Goddard, Ken A. Brameld, W. Goddard, 1998 .

DNA Interstrand Crosslinking by 2,5-Bis(1-aziridinyl)-1,4-benzoquinone: Nucleotide Sequence Preferences and Covalent Structure of the dG-to-dG Cross-Links at 5'-d(GNnC) in Synthetic Oligonucleotide Duplexes

S. Alley, K. Brameld, P. B. Hopkins, 1994 .

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

J. M. Bradshaw, E. Verner, D. Goldstein, 2022, Journal of medicinal chemistry.

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

J. M. Bradshaw, D. Goldstein, C. Langrish, 2021, The Journal of Immunology.

Efficacy in collagen induced arthritis models with a selective, reversible covalent Bruton’s tyrosine kinase inhibitor PRN473 is driven by durable target occupancy rather than extended plasma exposure (THER5P.904)

J. Funk, E. Verner, D. Goldstein, 2015, The Journal of Immunology.

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. M. Bradshaw, Jack Taunton, Sergei Romanov, 2015, Nature chemical biology.

Distance Dependent Hydrogen Bond Potentials for Nucleic Acid Base Pairs from ab Initio Quantum Mechanical Calculations (LMP2/cc-pVTZ)

William A. Goddard, Siddharth Dasgupta, Ken A. Brameld, 1997 .

The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists

Christian Laurence, Jean-Yves Le Questel, Ken A. Brameld, 2009 .

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.

J. M. Bradshaw, M. Gerritsen, E. Venetsanakos, 2017, Journal of medicinal chemistry.

Ab Initio Quantum Mechanical Study of the Structures and Energies for the Pseudorotation of 5‘-Dehydroxy Analogues of 2‘-Deoxyribose and Ribose Sugars

W. Goddard, K. Brameld, 1999 .

Substrate assistance in the mechanism of family 18 chitinases: theoretical studies of potential intermediates and inhibitors.

W. Goddard, B. Imperiali, K. Brameld, 1998, Journal of molecular biology.

Title Page

D. Bertrand, M. Milla, F. Knoflach, 2018, Public Health Genomics.

Characterization of RO5126946, a Novel α7 Nicotinic Acetylcholine Receptor–Positive Allosteric Modulator

D. Bertrand, M. Milla, F. Knoflach, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Characterization of RO 5126946 , a Novel a 7 Nicotinic Acetylcholine Receptor – Positive Allosteric Modulator s

D. Bertrand, M. Milla, F. Knoflach, 2014 .

The role of enzyme distortion in the single displacement mechanism of family 19 chitinases.

W. Goddard, K. Brameld, 1998, Proceedings of the National Academy of Sciences of the United States of America.

The chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferences.

R. Hayward, D. Fidock, C. Specht, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Conformational Equilibria of β-Alanine and Related Compounds as Studied by NMR Spectroscopy

W. Goddard, Sindy H. Wei, E. Streed, 1998 .

The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance

J. M. Bradshaw, M. Gerritsen, E. Venetsanakos, 2017, Molecular Cancer Therapeutics.

Conformational analysis of aqueous pullulan oligomers: an effective computational approach☆

W. Goddard, D. Brant, K. Brameld, 2002 .

3-heterocyclyl quinolone inhibitors of the HCV NS5B polymerase.

J. Janc, J. Ho, K. Brameld, 2012, Bioorganic & medicinal chemistry letters.

The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists.

C. Laurence, K. Brameld, J. Graton, 2009, Journal of medicinal chemistry.

Ab initio derived spectroscopic quality force fields for molecular modeling and dynamics

W. Goddard, S. Dasgupta, K. Brameld, 1997 .